7,8-Dihydroxyflavone for Health & Longevity - Quick Reference Sheet

7,8-Dihydroxyflavone for Health & Longevity

Created on 07/24/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

7,8-Dihydroxyflavone is a plant molecule that switches on the same brain receptor as a natural growth protein. Animal studies fairly consistently show better memory, neuron protection, and improved mood, with weaker signals elsewhere. No completed human trials exist, so every benefit and dose is estimated from rodents. Promising but essentially unproven in people. (Full Review)

Protocol

Typical Amount
25–100 mg
Once daily; extrapolated from rodent ~5 mg/kg
Best Time
Morning
Late dosing could interfere with sleep
Administration
With dietary fat
Fat-containing meal improves absorption
Time to effect
Subjective Effects
Days to weeks
No validated human timeline; expectation effects possible

Benefits

Contraindications
  • Active cancer treatment
  • Active malignancy or history of TrkB-driven cancer
  • Pregnancy or breastfeeding
  • Children
  • Recent fracture or orthopedic surgery (first 6–12 weeks)
  • Significant liver or kidney impairment
Key Interactions
  • Antidepressants (SSRIs: sertraline, fluoxetine; SNRIs: venlafaxine)
  • MAO inhibitors (phenelzine, selegiline)
  • Vitamin B6 supplements (pyridoxine)
  • Anticoagulants and antiplatelet drugs (warfarin, aspirin, clopidogrel)
  • Narrow-margin CYP1A2/CYP3A4 substrates (theophylline, certain statins)
  • Other BDNF-raising supplements and nootropics (other flavonoids, lion's mane)

Risk & Side Effects

  • Low: Impaired bone & fracture healing
  • Speculative: Unknown long-term human safety; vitamin B6 metabolism disruption; theoretical tumor-promotion risk; potentiation of addictive behaviors; pro-oxidant and off-target effects at high doses; product impurity, oxidation & mislabeling

Monitoring

Marker Target Why
ALT & AST ~10–26 U/L Screen liver stress from a compound cleared by the liver
Vitamin B6 (pyridoxal 5'-phosphate) ~30–80 nmol/L Detect disruption from pyridoxal phosphatase inhibition
Complete blood count Within standard reference limits Baseline safety screen for an untested agent
Fasting glucose & HbA1c Glucose ~75–90 mg/dL; HbA1c <5.4% Track the metabolic effects suggested in animal studies
Comprehensive metabolic panel Within standard reference limits Monitor kidney function and electrolytes over time

Cadence: Baseline before first dose; repeat at ~3 months, then every 6–12 months (sooner if any symptom arises)

Qualitative Assessment

  • Cognitive clarity and memory
  • Mood and stress resilience
  • Energy levels
  • Sleep quality